Carnitine palmitoyltransferase 2 as a novel prognostic biomarker and immunoregulator in colorectal cancer
The FAO-dominated MRGPI is a promising biomarker for predicting patient outcomes and immunotherapy response. CPT2 holds potential as a prognostic marker and therapeutic target for CRC metabolic immunotherapy.
Authors
- Ruo-Fei Tian
- Ke Yuan (ORCID: https://orcid.org/0000-0002-2318-1460)
- Zhi‐Nan Chen (ORCID: https://orcid.org/0000-0001-5512-4623)
- Fei Huo (ORCID: https://orcid.org/0000-0002-3402-2190)
- Longxiang Feng (ORCID: https://orcid.org/0009-0006-6701-6594)
- Xiulin Fan (ORCID: https://orcid.org/0000-0001-7294-480X)
- Hong‐Yong Cui (ORCID: https://orcid.org/0000-0003-0051-2666)
- Xue Liang (ORCID: https://orcid.org/0000-0001-6864-7386)
- Ling Li (ORCID: https://orcid.org/0000-0003-0083-6978)
- Hao Wang (ORCID: https://orcid.org/0000-0001-9990-2714)
- Ying Shi (ORCID: https://orcid.org/0000-0002-4241-5760)
- Jing Fan (ORCID: https://orcid.org/0000-0003-0072-5661)
- Jiajia Zhang (ORCID: https://orcid.org/0009-0009-9813-8895)
- Ting Yang (ORCID: https://orcid.org/0009-0004-6365-0905)
- Xin Fu (ORCID: https://orcid.org/0000-0001-8028-3597)
Institutions
- Wuhan University (CN)
- Bay Area Hospital (US)
- Zhongnan Hospital of Wuhan University (CN)
- General Hospital of Shenyang Military Region (CN)
- Xijing Hospital (CN)
- Air Force Medical University (CN)
Publication Details
- Journal
- International Journal of Biological Macromolecules
- Published
- 2025-04-08
- DOI
- https://doi.org/10.1016/j.ijbiomac.2025.142945
- Primary Topic
- Cancer, Lipids, and Metabolism
- Type
- article
- Field-Weighted Citation Impact
- 0.00